Reviewer’s report

Title: Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel group study

Version: 4 Date: 19 March 2013

Reviewer: Ronna Fried

Reviewer’s report:

The question of quality of life improvement for adults with ADHD and executive functioning deficits (EFDs) is an important clinical and public health issue and thus treatment studies for it amelioration are very important. The numbers in the study and the methods are well described.

Discretionary Revision: The Background of the abstract states that the study examined the effects of LDX on QOL in adults with ADHD and EFDS, however the primary efficacy measure is described as being the BRIEF-A and thus it is a bit confusing. Perhaps the QOL should be in the first sentence of the Methods.

Level of interest: An article of outstanding merit and interest in its field

Quality of written English: Acceptable

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:

I declare that I have no competing interests